Compare NUTX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | OGN |
|---|---|---|
| Founded | 2011 | 1923 |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2009 | 2020 |
| Metric | NUTX | OGN |
|---|---|---|
| Price | $193.24 | $13.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $252.50 | $11.40 |
| AVG Volume (30 Days) | 135.6K | ★ 3.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 7.93 | N/A |
| EPS | ★ 15.87 | 0.95 |
| Revenue | $875,257,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $6.12 | $0.45 |
| Revenue Next Year | $4.04 | $1.67 |
| P/E Ratio | ★ $12.26 | $14.49 |
| Revenue Growth | ★ 82.36 | N/A |
| 52 Week Low | $80.53 | $5.69 |
| 52 Week High | $204.00 | $13.79 |
| Indicator | NUTX | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.84 | 74.07 |
| Support Level | $142.71 | $13.46 |
| Resistance Level | $204.00 | N/A |
| Average True Range (ATR) | 8.54 | 0.03 |
| MACD | -0.23 | -0.01 |
| Stochastic Oscillator | 77.16 | 87.50 |
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.